Please login to the form below

Not currently logged in
Email:
Password:

Prostvac

This page shows the latest Prostvac news and features for those working in and with pharma, biotech and healthcare.

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

CV301 is Bavarian Nordic’s lead cancer vaccine after its much-delayed Prostvac candidate for prostate cancer failed to meet the mark in a phase III trial last year, wreaking havoc ... The setback was also a big disappointment for Bristol-Myers Squibb

Latest news

  • BMS signs $975m deal for Bavarian Nordic cancer vaccine BMS signs $975m deal for Bavarian Nordic cancer vaccine

    Furthermore, Bavarian Nordic could also receive regulatory milestone payments of $110m, up to $495m in sales milestones as well as tiered double-digit royalties on future sales of Prostvac. ... Analysts at Edison Research have predicted that Prostvac

  • Developing therapeutic cancer vaccines Developing therapeutic cancer vaccines

    Viral-vector based vaccines are also in the works. BN ImmunoTherapeutics and the US NCI are developing a viral-vector based vaccine, rilimogene galvacirepvec-rilimogene glafolivec (PROSTVAC), which is in phase

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...